首页> 外文期刊>The Journal of Reproduction and Development >Efficient mutagenesis by CRISPR/Cas system during meiotic maturation of porcine oocytes
【24h】

Efficient mutagenesis by CRISPR/Cas system during meiotic maturation of porcine oocytes

机译:CRISPR / Cas系统在猪卵母细胞减数分裂成熟过程中的高效诱变

获取原文
           

摘要

Genome editing using the CRISPR/Cas system can induce mutations with high efficiency, and allows easier production of genome-modified animals than that offered by the conventional method where embryonic stem cells are used. However, studies using CRISPR/Cas systems have been mostly limited to proliferating somatic cells and pronuclear-stage fertilized eggs. In contrast, the efficiency of a CRISPR/Cas system in immature and maturing oocytes progressing through meiosis has not yet been assessed. In the present study, we evaluated the genome-modification efficiency of the CRISPR/Cas system during meiotic maturation of porcine oocytes. Additionally, the localization of the Cas9 protein in immature oocytes was analyzed in relation to nuclear transport and mutation induction. The results showed that CRISPR/Cas induced mutation with high efficiency even in maturing oocytes with condensed chromosomes, whereas mutations were not induced in GV-stage oocytes. The localization analysis of enhanced green fluorescent protein (EGFP)-tagged Cas9 (Cas9-EGFP) revealed that the nuclei contained lesser Cas9 than the cytoplasm in immature oocytes. Treatment with leptomycin B, a nuclear export inhibitor, increased the amount of nuclear Cas9 and enabled mutation induction in GV oocytes. Our results suggest that CRISPR/Cas systems can be applied to oocytes during meiotic maturation and be implemented in novel applications targeting female genomes.
机译:与使用胚胎干细胞的常规方法相比,使用CRISPR / Cas系统进行的基因组编辑可以高效诱导突变,并且可以更容易地生产经基因组修饰的动物。然而,使用CRISPR / Cas系统的研究主要限于增殖体细胞和前核阶段受精卵。相反,尚未评估CRISPR / Cas系统在通过减数分裂的未成熟和成熟卵母细胞中的效率。在本研究中,我们评估了猪卵母细胞减数分裂成熟过程中CRISPR / Cas系统的基因组修饰效率。此外,分析了Cas9蛋白在未成熟卵母细胞中的定位,与核转运和突变诱导有关。结果表明,即使在具有浓缩染色体的成熟卵母细胞中,CRISPR / Cas仍能高效诱导突变,而在GV期卵母细胞中却没有诱导突变。增强的绿色荧光蛋白(EGFP)标记的Cas9(Cas9-EGFP)的定位分析表明,在未成熟卵母细胞中,细胞核中的Cas9比细胞质少。用核输出抑制剂leptomycin B进行治疗,可增加Cas9核的数量,并能在GV卵母细胞中诱导突变。我们的结果表明,CRISPR / Cas系统可以在减数分裂成熟期间应用于卵母细胞,并可以在针对女性基因组的新型应用中实现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号